Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy

American Heart Journal

Volumn 156, Issue 1, 2008, Pages 85-91

  Roldán, Vanessa ^a,b   Marín, Francisco ^b,c,d   Gimeno, Juan R ^b,d   Ruiz Espejo, Francisco ^b,d   González, Josefa ^d   Feliu, Eloisa ^c   García Honrubia, Antonio ^c   Saura, Daniel ^d   de la Morena, Gonzalo ^d   Valdés, Mariano ^d   Vicente, Vicente ^a,b  

^a UNIVERSITY OF MURCIA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GADOLINIUM PENTETATE; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE;

ADULT; ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DYSPNEA; ECHOCARDIOGRAPHY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE; FEMALE; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART VENTRICLE OVERLOAD; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK FACTOR; SEX; STATISTICAL SIGNIFICANCE; SUDDEN DEATH;

ADULT; BIOLOGICAL MARKERS; CARDIOMYOPATHY, HYPERTROPHIC; CASE-CONTROL STUDIES; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; PROBABILITY; PROGNOSIS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VENTRICULAR REMODELING;

EID: 45549084433     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.01.035     Document Type: Article

References (33)

1. Libby P., and Lee R.T. Matrix matters. Circulation 102 (2000) 1874-1876
2. Spinale F.G. Matrix metalloproteinases. Regulation and dysregulation in the failing heart. Circ Res 90 (2002) 520-530
3. Jalil J.E., Doering C.W., Janicki J.S., et al. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 64 (1989) 1041-1050
4. Frohlich E.D. Risk mechanisms in hypertensive heart disease. Hypertension 34 part 2 (1999) 782-789
5. Laviades C., Varo N., Fernández J., et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 98 (1998) 535-540
6. Thomas C.V., Coker M.L., Zellner J.L., et al. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 97 (1998) 1708-1715
7. Spinale F.G., Coker M.L., Heung L.J., et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 102 (2000) 1944-1949
8. Jordán A., Roldán V., García M., et al. Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in congestive heart failure: relation to functional data and prognosis. J Intern Med 262 (2007) 385-392
9. Elliot P., and McKenna W.J. Hypertrophic cardiomyopathy. Lancet 363 (2004) 1881-1891
10. Maron B.J., Bonow R.O., Cannon R.O., et al. Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy. N Eng J Med 316 (1987) 780-844
11. Maron B.J. Hypertrophic cardiomyopathy: a systematic review. JAMA 287 (2002) 1308-1320
12. Lombardi R., Betocchi S., Losi M.A., et al. Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation 108 (2003) 1455-1460
13. Noji Y., Shimizu M., Ino H., et al. Increased circulating matrix metalloproteinase-2 in patients wit hypertrophic cardiomyopathy with systolic dysfunction. Circ J 68 (2004) 355-360
14. Fassbach M., and Schwartzkopff B. Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction. Z Cardiol 94 (2005) 328-335
15. McCullough P.A., Nowak R.M., McCord J., et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) multinational study. Circulation 106 (2002) 416-422
16. Maron B.J., Tholakanahalli V.N., Zenovich A.G., et al. Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation 109 (2004) 984-989
17. Briguori C., Betocchi S., Maganelli F., et al. Determinants and clinical significance of natriuretic peptides in hypertrophic cardiomyopathy. Eur Heart J 22 (2001) 1328-1336
18. Tsuruda T., Boerringter G., Huntley B.K., et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 91 (2002) 1127-1134
19. Moon J.C., Reed E., Sheppard M.N., et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 43 (2004) 2260-2264
20. Dumont C.A., Monserrat Soler R., Rodríguez E., et al. Clinical significance of late gadolinium enhancement on cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy. Rev Esp Cardiol 60 (2007) 15-23
21. McKenna W.J., Spirito P., Desnos M., et al. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart 77 (1997) 130-132
22. Shirani J., Pick R., Roberts W.C., et al. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiiol 35 (2000) 36-44
23. Marian A.J., Senthil V., Chen S.N., et al. Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. J Am Coll Cardiol 47 (2006) 827-834
24. Yamazaki T., Lee J.D., Shimizu H., et al. Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure. Eur J Heart Fail 6 (2004) 41-45
25. Latini R., Masson S., Anand I., et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure in Val-Heft. Eur Heart J 25 (2004) 292-299
26. Thaman R., Esteban M.T., Barnes S., et al. Usefulness of N-terminal pro-B-type natriuretic Peptide levels to predict exercise capacity in hypertrophic cardiomyopathy. Am J Cardiol 98 (2006) 515-519
27. Moon J.C., McKenna W., McCrohon J.A., et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 41 (2003) 1561-1571
28. Wilson J.M., Villareal R.P., Hariharan R., et al. Magnetic resonance imaging of myocardial fibrosis in hypertrophic cardiomyopathy. Tex Heart Inst J 29 (2002) 176-180
29. Moon J.C. What is late gadolinium enhancement in hypertrophic cardiomyopathy?. Rev Esp Cardiol 60 (2007) 1-4
30. Ducharme A., Frantz S., Aikawa M., et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106 (2000) 55-62
31. Heymans S., Lupu F., Terclavers S., et al. Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol 166 (2005) 15-25
32. Moshal K.S., Tyagi N., Moss V., et al. Early induction of matrix metalloproteinase-9 transducers signalling in human heart end stage failure. J Cell Mol Med 9 (2005) 704-713
33. Thaman R., Gimeno J.R., Reith S., et al. Progressive left ventricular remodelling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy. J Am Coll Cardiol 44 (2004) 398-405